In a recent publication, scientists from Inotiv and NanoPharmaceuticals evaluate potential drug-drug interactions (DDI) with a novel anticancer thyrointegrin αvβ3 antagonist, fb-PMT. Their assessment included CYP metabolism, CYP inhibition, CYP induction, and fb-PMT as a substrate or inhibitor of several ABC and SLC transporters.
